• Seres Therapeutics disclosed new preclinical data supporting SER-603, a next-generation cultivated live biotherapeutic candidate for inflammatory bowel disease, with results presented at Digestive Disease Week 2026.
• Data supported SER-603 design strategy aimed at reducing gastrointestinal inflammatory triggers while promoting mucosal healing, positioning it as a potential non-immunosuppressive option that could be used alone or alongside existing biologics.
• Company also highlighted microbiome-based biomarkers intended to guide patient stratification and predict response to biologics, a step that could shape future trial design and commercial positioning.
• Program is in IND-enabling work, with discussions underway with potential collaborators to support clinical development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Seres Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605040700PRIMZONEFULLFEED9712074) on May 04, 2026, and is solely responsible for the information contained therein.